IP Library Granted Patent US 7,960,409
Granted Patent B2
US 7,960,409 · App. 12/012,246 · Granted Jun 14, 2011

Pharmaceutical phenylquinoline and chromen-2-one triazole compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,960,409
App. No.
12/012,246
Granted
Jun 14, 2011
Kind
B2
Abstract

The instant invention provides compounds of Formula I which are leukotriene biosynthesis inhibitors. Compounds of Formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.

Claims (178)

1. A compound of structural Formula I

or a pharmaceutically acceptable salt thereof wherein:

is selected from the group consisting of

wherein the numbers “1” and “2” indicate the points of attachment within structural Formula I;

 is selected from a single and a double bond;

A is selected from the group consisting of:

(a) a 5-membered heteroaryl ring containing (i) one or more carbon atoms, (ii) one heteroatom selected from oxygen and sulfur, and (iii) zero, one, two or three nitrogen atoms,

(b) a 5-membered heteroaryl ring containing one or more carbon atoms and from one to four nitrogen atoms,

(c) a 6-membered heteroaryl ring containing carbon atoms and one, two or three nitrogen atoms,

(d) a bicyclic ring system selected from benzothienyl, indolyl, quinolinyl and naphthalenyl,

(e) morpholinyl,

(f) phenyl,

(g) benzyl,

(h) chloro, and

(i) —C(O)C 1-3 alkyl,

and wherein A is optionally mono-or di-substituted with a substituent independently selected at each occurrence from the group consisting of (i) fluorine, (ii) chlorine, (iii) —C 1-3 alkyl optionally substituted with one to five fluorines, (iv) —C 1-3 alkoxy optionally substituted with one to five fluorines, (v) C 3-6 cycloalkyloxy, (vi) —C 1-3 alkyl-OH, (vii) —COOR 8 , (viii) —CN, (ix) —NR 7 R 8 , and (x) —SO 2 C 1-3 alkyl;

W is H or methyl;

X is selected from the group consisting of pyridinyl, -Ph, and —C(R 2 )(R 3 )(R 4 );

Y is selected from —CH 2 —and —CH 2 CH 2 —;

R 1 is selected from the group consisting of —H, —C 1-6 alkyl and —C 3-6 cycloalkyl;

R 1a is selected from the group consisting of: (a) —H, (b) —Cl, (c) —CN, (d) —COOR 8 , (e)—CONR 7 R 8 , (f) —C(S)NR 7 R 8 , (g) —S(O) p —C 1-3 alkyl, (h) —NR 7 R 9 , (i) —C(═N—OH)—CH 3 , (j) —C(═N—OCH 3 )—CH 3 , (k) —C(═NH)—OCH 3 , (l) —C 1-6 alkyl optionally mono-or di-substituted with a substituent independently selected at each occurrence from the group consisting of —OH and —F, (m) —C 1-3 alkyl-O—C 1-3 alkyl, (n) —C 1-3 alkoxy optionally substituted with one to five fluorines, (o) —C 1-3 alkoxy, (p) —C 3-6 cycloalkyl, (q) phenyl optionally mono-or di-substituted with a substituent independently selected at each occurrence from the group consisting of —OH and —F, (r) pyridinyl optionally substituted with —C 1-3 alkyl, particularly methyl, (s) 1-pyrrolidinyl, (t) 4-morpholinyl, and (u) 1-piperazinyl optionally 4N-substituted with —C 1-3 alkyl particularly methyl;

p is an integer selected from zero, 1 and 2;

R 2 is selected from the group consisting of —H, —OH, —F, —C 1-3 alkyl, —OC 1-3 alkyl, —OC(O)—C 1-3 alkyl, and —OC(O)-phenyl wherein phenyl is optionally substituted with a group selected from —OH and —NO 2 ; and —O-cyclic alkyl ether wherein the cyclic alkyl ether is comprised of one oxygen and 2-5 carbon atoms;

R 3 is selected from the group consisting of —H, —C 1-6 alkyl, —C 1-6 alkyl substituted with one or more of fluoro, —C 1-6 alkyl substituted with R 6 , phenyl, —C 2-6 alkenyl, —C 3-6 cycloalkyl, and —C 5-7 cycloalkenyl;

R 4 is selected from the group consisting of —H, —C 1-6 alkyl, —C 1-6 alkyl substituted with one or more of fluoro, —C 1-6 alkyl substituted with R 6 , phenyl, —C 2-6 alkenyl, —C 3-6 cycloalkyl, and —C 5-7 cycloalkenyl;

or R 3 and R 4 are joined together with the carbon to which they are attached to form a ring selected from —C 3-6 cycloalkyl, and a 3-6 membered cyclic alkyl ether comprised of one oxygen and 2-5 carbon atoms; C 5-7 cycloalkenyl, provided that there is no double bond at the C-1 position in the ring;

or R 2 , R 3 and R 4 are joined together with the carbon to which they are attached to form 1-cyclopentenyl or 1-cyclohexenyl;

R 5 is independently selected at each occurrence from the group consisting of —H, —C 1-6 alkyl and —C 3-6 cycloalkyl;

R 6 is independently selected at each occurrence from the group consisting of —COOR 8 , —C(O)H, —CN, —CR 5 R 5 OH, —OR 5 , —S—C 1-6 alkyl and —S—C 3-6 cycloalkyl;

R 7 is selected from the group consisting of —H, —C 1-6 alkyl, —C 3-6 cycloalkyl and —COOR 8 ;

R 8 is selected from the group consisting of —H, —C 1-6 alkyl and —C 3-6 cycloalkyl; and

R 9 is independently selected from the group consisting of —H, —C 1-6 alkyl, and —C 3-6 cycloalkyl, phenyl and benzyl.

2. The compound of claim 1 having structural formual Ia

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 having structural formual Ib

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 having structural formual Ic

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 having structural formual Id

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 wherein A is selected from (a) a 5-membered aromatic ring containing 3-4 carbon atoms and 1-2 heteroatoms selected from nitrogen, oxygen and sulfur, (b) pyridinyl, and (c) phenyl; wherein A is optionally mono-or di-substituted.

7. The compound of claim 6 wherein R 1 is selected from —H and —C 1-6 alkyl, and R 1a is selected from the group consisting of —H, cyano, and —CONR 7 R 8 .

8. The compound of claim 6 wherein  is a double bond.

9. The compound of claim 8 wherein Y is selected from —CH 2 —.

10. The compound of claim 9 wherein X is is —CR 2 R 3 R 4 .

11. The compound of claim 10 wherein R 2 is selected from the group consisting of —H, —OH, —F, —C 1-3 alkyl, —OCH 3 , and —OC(O)CH 3 ; R 3 is selected from the group consisting of —H, —C 1-6 alkyl, —C 3-6 cycloalkyl, phenyl and —C 1-6 alkyl substituted with one or more of fluoro; and R 4 is selected from the group consisting of —H, —C 1-6 alkyl, —C 3-6 cycloalkyl, —C 1-6 alkyl substituted with one or more of fluoro, and —C 1-6 alkyl substituted with R 6 .

12. The compound of claim 1 selected from the group consisting of:

4-(3-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-2H-chromen-2-one;

4-(4-Fluorophenyl)-7-[4-(1-hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;

4-(2-Fluoro-phenyl)-7-[4-(1-hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;

4-(3,5-Difluoro-phenyl)-7-[4-(1-hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;

7-[4-(1-Hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-4-phenyl-chromen-2-one;

4-(3-Chlorophenyl)-7-[4-(1-hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;

4-(4-Chlorophenyl)-7-[4-(1-hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;

7-[4-(1-Hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-4-thiophen-3-yl-chromen-2-one;

4-(3-Ethoxy-phenyl)-7-[4-(1-hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;

7-[4-(1-Hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-4-(3-trifluoromethoxy-phenyl)-chromen-2-one;

7-[4-(1-Hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-4-(3-methoxy-phenyl)-chromen-2-one;

7-[4-(1-Ethyl-1-hydroxy-propyl)-[1,2,3]triazol-1-ylmethyl]-4-(3-fluoro-phenyl)-chromen-2-one;

7-[4-(1-Ethyl-1-hydroxy-propyl)-[1,2,3]triazol-1-ylmethyl]-4-(3-methoxy-phenyl)-chromen-2-one;

7-[4-(1-Ethyl-1-hydroxy-propyl)-[1,2,3]triazol-1-ylmethyl]-4-(4-methoxy-phenyl)-chromen-2-one;

7-[4-(1-Ethyl-1-hydroxy-propyl)-[1,2,3]triazol-1-ylmethyl]-4-phenyl-chromen-2-one;

7-[4-(1-Ethyl-1-hydroxy-propyl)-[1,2,3]triazol-1-ylmethyl]-4-(4-fluoro-phenyl)-chromen-2-one;

4-(4-Fluoro-phenyl)-7-[4-(tetrahydro-pyran-2-yloxymethyl)-[1,2,3]triazol-1-ylmethyl]chromen-2-one;

4-(4-Fluoro-phenyl)-7-[4-(1-hydroxy-1-phenyl-ethyl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;

4-(4-Fluoro-phenyl)-7-[4-(4-hydroxy-tetrahydro-pyran-4-yl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;

4-(4-Fluoro-phenyl)-7-[4-(4-methoxy-tetrahydro-pyran-4-yl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;

4-(3-fluorophenyl)-7-[(4-phenyl-1H-1,2,3-triazol-1-yl)methyl]-2H-chromen-2-one;

7-[(4-benzyl-1H-1,2,3-triazol-1-yl)methyl]-4-(3-fluorophenyl)-2H-chromen-2-one;

4-(4-Fluorophenyl)-7-[4-(1-oxy-pyridin-2-yl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;

7-[4-(Dicyclopropyl-hydroxy-methyl)-[1,2,3]triazol-1-ylmethyl]-4-(3-fluoro-phenyl)-chromen-2-one;

7[4-(Dicyclopropyl-hydroxy-methyl)-[1,2,3]triazol-1-ylmethyl]-4-(4-fluoro-phenyl)-chromen-2-one;

4-(3-fluorophenyl)-7-{[4-(1-hydroxy-1-(trifluoromethyl)propyl)-5-methyl-1H-1,2,3-triazol-1-yl}methyl]-2H-chromen-2-one;

4-(4-Fluorophenyl)-7-[({5-[1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl}-amino)methyl]-6-methyl-2H-chromen-2-one;

7-{[4-(1-Cyclopropyl-2,2,2-trifluoro-1-hydroxyethyl)-1H-1,2,3-triazol-1-yl]methyl}-4-(3-fluorophenyl)-2H-chromen-2-one;

4-(3-Fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)butyl]-1H-1,2,3-triazol-1-yl}methyl)-2H-chromen-2-one;

4-(3-Methylphenyl)-7-({4-[1-ethyl-1-hydroxypropyl]-1H-1,2,3-triazol-1-yl}methyl)-2H-chromen-2-one;

7-[4-(1-Ethyl-1-hydroxy-propyl)-[1,2,3]triazol-1-ylmethyl]-4-pyridin-3-yl-chromen-2-one;

7({4[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(5-methylisoxazol-3-yl)-2H-chromen-2-one;

7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(1,3-thiazol-2-yl)-2H-chromen-2-one;

7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(3-methoxyisoxazol-5-yl)-2H-chromen-2-one;

7-[4-(1-Hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-4-isothiazol-5-yl-chromen-2-one;

7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(2-methyl-1,3-oxazol-4-yl)-2H-chromen-2-one;

7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(2-methyl-1,3-thiazol-4-yl)-2H-chromen-2-one;

7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-phenylquinoline-2-carbonitrile;

4-(3-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;

4-(4-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;

7-({4-[ 1 -hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-phenylquinoline -2-carboxylic acid;

7-{[4-(1-ethyl-1-hydroxypropyl)-1H-1,2,3-triazol-1-yl]methyl}-4-phenylquinoline-2-carbonitrile;

7-{[4-(1-ethyl-1-hydroxypropyl)-1H-1,2,3-triazol-1-yl]methyl}-4-(4-fluorophenyl)quinoline-2-carbonitrile;

7-{[4-(1-ethyl-1-hydroxypropyl)-1H-1,2,3-triazol-1-yl]methyl}-4-(3-fluoro-phenyl)quinoline -2-carbonitrile;

7-({4-[dicyclopropyl(hydroxy)methyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(4-fluorophenyl)quinoline-2-carbonitrile;

7-({4-[dicyclopropyl(hydroxy)methyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(3-fluorophenyl)quinoline-2-carbonitrile;

7-({4-[dicyclopropyl(hydroxy)methyl]-1H-1,2,3-triazol-1-yl}methyl)-4-phenylquinoline-2-carbonitrile;

7-{[4-(1-hydroxycyclopentyl)-1H-1,2,3-triazol-1-yl]methyl}-4-phenylquinoline-2-carbonitrile;

7-{[4-(1-methoxycyclopentyl)-1H-1,2,3-triazol-1-yl]methyl}-4-phenylquinoline-2-carbonitrile;

4-chloro-7-({4-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile

7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(2-methyl-1,3-oxazol-4-yl)quinoline-2-carbonitrile;

7-({4-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl }methyl)-4-(2-methyl-1,3-thiazol-4-yl)quinoline-2-carbonitrile;

4-acetyl-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;

7-({4-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(1,3-thiazol-4-yl)quinoline-2-carbonitrile;

4-(3,4-difluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;

4-(3,5-dichlorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;

4-(3,5-difluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;

4-(4-chlorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;

4-(3-chlorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;

4-(4-fluoro-3-methylphenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;

7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-pyridin-3-ylquinoline-2-carbonitrile;

7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-pyrimidin-5-ylquinoline-2-carbonitrile;

4-[3-(dimethylamino)phenyl]-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;

7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(4-methylphenyl)quinoline-2-carbonitrile;

7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(3-methylphenyl)quinoline-2-carbonitrile;

7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-[3-(methylsulfonyl)phenyl]quinoline-2-carbonitrile;

4-(3,5-dichlorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carboxamide;

7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-phenylquinoline-2-carboxamide;

4-(3-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carboxamide;

4-(4-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carboxamide;

4-(3,4-difluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carboxamide;

4-(3,5-difluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carboxamide;

4-(4-chlorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carboxamide;

4-(3-chlorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carboxamide;

4-(4-fluoro-3-methylphenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carboxamide;

7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(4-methylphenyl)quinoline-2-carboxamide;

7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl }methyl)-4-(3-methylphenyl)quinoline-2-carboxamide;

7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-[3-(methylsulfonyl)phenyl]quinoline-2-carboxamide;

4-chloro-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carboxamide;

2-(1-{[2-chloro-4-(4-fluorophenyl)quinolin-7-yl]methyl }-1H-1,2,3-triazol-4-yl)-1,1,1-trifluorobutan-2-ol;

2-(1-{[2-amino-4-(4-fluorophenyl)quinolin-7-yl]methyl }-1H-1,2,3-triazol-4-yl)-1,1,1-trifluorobutan-2-ol;

2-(1-{[2-(benzylamino)-4-(4-fluorophenyl)quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)-1,1,1-trifluorobutan-2-ol;

1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-pyrrolidin-1-ylquinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;

1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-(4-methylpiperazin-1-yl) quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;

1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-morpholin-4-ylquinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;

2-(1-{[2-(dimethylamino)-4-(4-fluorophenyl)quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)-1,1,1-trifluorobutan-2-ol;

1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-methoxyquinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;

1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-(2,2,2-trifluoroethoxy)quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;

1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-(methylthio)quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;

1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-(methylsulfonyl)quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;

2-(1-{[2-cyclopropyl-4-(4-fluorophenyl)quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)-1,1,1-trifluorobutan-2-ol;

1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-phenylquinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;

1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-pyridin-3-ylquinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;

1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-methylquinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;

1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)quinolin-7-yl]methyl}-1H-1,2 ,3-triazol-4-yl)butan-2-ol;

1-[4-(4-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinolin-2-yl]ethanone;

1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-(1-hydroxy-1-methylethyl)quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;

1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-(1-hydroxyethyl)quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;

1,1,1-trifluoro-2-(1-{[4-(4-fluorophenyl)-2-(1-methoxyethyl)quinolin-7-yl]methyl}-1H-1,2,3-triazol-4-yl)butan-2-ol;

(1Z)-1-[4-(4-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinolin-2-yl]ethanone oxime;

(1E)-1-[4-(4-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinolin-2-yl]ethanone O-methyloxime;

7-{2-[4-(1-ethyl-1-hydroxypropyl)-1H-1,2,3-triazol-1-yl]ethyl}-4-phenylquinoline-2-carbonitrile; and

7-(2-{4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}ethyl)-4-phenylquinoline-2-carbonitrile ;

or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1 selected from the group consisting of:

4-(3-chlorophenyl)-7-[4(1-hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;

4-(4-chlorophenyl)-7-[4-(1-hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one

7-[4-(1-hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-4-thiophen-3-yl-chromen-2-one;

7-[4-(dicyclopropyl-hydroxy-methyl)-[1,2,3]triazol-1-ylmethyl]-4-(3-fluoro-phenyl)-chromen-2-one;

7-{[4-(1-cyclopropyl-2,2,2-trifluoro-1-hydroxyethyl)-1H-1,2,3-triazol-1-yl]methyl}-4-(3-fluorophenyl)-2H-chromen-2-one;

7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-(2-methyl-1,3-thiazol-4-yl)-2H-chromen-2-one;

4-(4-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;

7-{[4-(1-ethyl-1-hydroxypropyl)-1H-1,2,3-triazol-1-yl]methyl}-4-(4-fluorophenyl)quinoline-2-carbonitrile;

7-{[4-(1-ethyl-1-hydroxypropyl)-1H-1,2,3-triazol-1-yl]methyl}-4-(3-fluoro-phenyl)quinoline-2-carbonitrile; and

7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-pyridin-3-ylquinoline-2-carbonitrile;

or a pharmaceutically acceptable salt thereof.

14. The compound of claim 1 selected from the group consisting of:

4-(3-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-2H-chromen-2-one;

4-(4-fluorophenyl)-7-[4-(1-hydroxy-1-trifluoromethyl-propyl)-[1,2,3]triazol-1-ylmethyl]-chromen-2-one;

7-[4-(1-hydroxy-1-trifluoromethyl-propyl)[1,2,3]triazol-1-ylmethyl]-4-phenyl-chromen-2-one

7-({4[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-phenylquinoline-2-carbonitrile;

4-(3-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carbonitrile;

7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-phenylquinoline-2-carboxamide; and

4-(4-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)quinoline-2-carboxamide;

or a pharmaceutically acceptable salt thereof.

15. A compound of claim 1 which is (S)-4-(3-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-2H-chromen-2-one or a pharmaceutically acceptable salt thereof.

16. A compound of claim 1 which is (S)-4-(4-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-2H-chromen-2-one or a pharmaceutically acceptable salt thereof.

17. A compound of claim 1 which is (S)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-phenyl-2H-chromen-2-one or a pharmaceutically acceptable salt thereof.

18. A compound of claim 1 which is (S)-7-({4[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-phenylquinoline-2-carbonitrile or a pharmaceutically acceptable salt thereof.

19. A compound of claim 1 which is (S)-7-({4[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-4-phenylquinoline-2-carboxamide or a pharmaceutically acceptable salt thereof.

20. A pharmaceutical composition comprised of a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2014
From: MERCK SHARP & DOHME CORP.
To: MERCK CANADA INC.
Reel/Frame 033113/0383 →
CHANGE OF NAME Recorded Aug 29, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028866/0511 →
MERGER Recorded Aug 27, 2012
From: MERCK SHARP & DOHME CORP.
To: SCHERING CORPORATION
Reel/Frame 028850/0515 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2008
From: GRIMM, ERICH L.; DUCHARME, YVES; FRIESEN, RICHARD; JUTEAU, HELENE; LALIBERTE, SEBASTIEN; MACKAY, BRUCE; GAREAU, YVES; GAGNON, MARC; FRENETTE, RICHARD
To: MERCK FROSST CANADA LTD.
Reel/Frame 021836/0619 →